Related references
Note: Only part of the references are listed.Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology
Neal I. Lindeman et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2018)
Radiosynthesis and biological evaluation of 18F-labeled 4-anilinoquinazoline derivative (18F-FEA-Erlotinib) as a potential EGFR PET agent
Shun Huang et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2018)
Liquid Biopsy in Lung Cancer: Clinical Applications of Circulating Biomarkers (CTCs and ctDNA)
Minji Lim et al.
MICROMACHINES (2018)
Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer
Hazem I. Assi et al.
CANCER (2018)
Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
Nasser Hanna et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Subclonal Therapy by Two EGFR TKIs Guided by Sequential Plasma Cell-free DNA in EGFR -Mutated Lung Cancer
Nir Peled et al.
Journal of Thoracic Oncology (2017)
A multi species evaluation of the radiation dosimetry of [11C]erlotinib, the radiolabeled analog of a clinically utilized tyrosine kinase inhibitor
J. Ryan Petrulli et al.
NUCLEAR MEDICINE AND BIOLOGY (2017)
[11C]Erlotinib PET cannot detect acquired erlotinib resistance in NSCLC tumor xenografts in mice
Alexander Traxl et al.
NUCLEAR MEDICINE AND BIOLOGY (2017)
Targeting EGFR T790M mutation in NSCLC: From biology to evaluation and treatment
Antonio Passaro et al.
PHARMACOLOGICAL RESEARCH (2017)
68Ga labeled Erlotinib: A novel PET probe for imaging EGFR over-expressing tumors
Akanksha Jain et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2017)
Radiomic Features Are Associated With EGFR Mutation Status in Lung Adenocarcinomas
Ying Liu et al.
CLINICAL LUNG CANCER (2016)
The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016
Daniel S. W. Tan et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Limits and potential of targeted sequencing analysis of liquid biopsy in patients with lung and colon carcinoma
Anna Maria Rachiglio et al.
ONCOTARGET (2016)
Effects of erlotinib therapy on [11C]erlotinib uptake in EGFR mutated, advanced NSCLC
Idris Bahce et al.
EJNMMI RESEARCH (2016)
Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer
Adrian G. Sacher et al.
JAMA ONCOLOGY (2016)
Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy
Tony Mok et al.
CLINICAL CANCER RESEARCH (2015)
EGFR mutations in lung cancer: from tissue testing to liquid biopsy
Francesca Fenizia et al.
FUTURE ONCOLOGY (2015)
A comparative PET imaging study with the reversible and irreversible EGFR tyrosine kinase inhibitors [11C]erlotinib and [18F]afatinib in lung cancer-bearing mice
Paul Slobbe et al.
EJNMMI RESEARCH (2015)
Identifying erlotinib-sensitive non-small cell lung carcinoma tumors in mice using [11C]erlotinib PET
Galith Abourbeh et al.
EJNMMI RESEARCH (2015)
Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
Mark G. Kris et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
A fully-automated one-pot synthesis of [18F]fluoromethylcholine with reduced dimethylaminoethanol contamination via [18F]fluoromethyl tosylate
Melissa E. Rodnick et al.
APPLIED RADIATION AND ISOTOPES (2013)
Development of [11C]erlotinib Positron Emission Tomography for In Vivo Evaluation of EGF Receptor Mutational Status
Idris Bahce et al.
CLINICAL CANCER RESEARCH (2013)
Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology
Neal I. Lindeman et al.
JOURNAL OF THORACIC ONCOLOGY (2013)
Quantitative Analysis of [11C]-Erlotinib PET Demonstrates Specific Binding for Activating Mutations of the EGFR Kinase Domain
J. Ryan Petrulli et al.
NEOPLASIA (2013)
PET imaging with small-molecule tyrosine kinase inhibitors: TKI-PET
Paul Slobbe et al.
DRUG DISCOVERY TODAY (2012)
PET imaging with radiolabeled antibodies and tyrosine kinase inhibitors: immuno-PET and TKI-PET
Guus A. M. S. van Dongen et al.
TUMOR BIOLOGY (2012)
PET imaging of patients with non-small cell lung cancer employing an EGF receptor targeting drug as tracer
A. A. Memon et al.
BRITISH JOURNAL OF CANCER (2011)
Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay
Maria E. Arcila et al.
CLINICAL CANCER RESEARCH (2011)
American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non-Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy
Vicki Leigh Keedy et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Erlotinib Accumulation in Brain Metastases from Non-small Cell Lung Cancer: Visualization by Positron Emission Tomography in a Patient Harboring a Mutation in the Epidermal Growth Factor Receptor
Britta Weber et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
EGFR testing in lung cancer is ready for prime time
Fred R. Hirsch et al.
LANCET ONCOLOGY (2009)
Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib
Kendall D. Carey et al.
CANCER RESEARCH (2006)
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib
DA Eberhard et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib
SW Han et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Share Paper
